Page 64 - Demo

https://clinicaltrials.gov/study/NCT02149225.16. Precision-Life-Science-Group. A Randomized,Double-blind, Controlled Phase IIb Study ofthe Safety and Efficacy of ICT-107 in NewlyDiagnosed Patients With GlioblastomaMultiforme (GBM) Following Resection andChemoradiation 2017 [Available from:https://clinicaltrials.gov/study/NCT01280552.17. Mayo-Clinic. Pilot Clinical Trial of AllogeneicTumor Lysate-Pulsed Autologous DendriticCell Vaccination in Recurrent Glioblastoma2023 [Available from:https://clinicaltrials.gov/study/NCT0336070818. Fuente-MDL. Dendritic Cell Vaccine ForMalignant Glioma and GlioblastomaMultiforme in Adult and Pediatric Subjects2022 [Available from:https://clinicaltrials.gov/study/NCT0180882019. The-Cooper-Health-System. A Phase I Study ofTh-1 Dendritic Cell Immunotherapy inCombination With Standard Chemoradiationfor the Adjuvant Treatment of AdultGlioblastoma 2024 [Available from:https://clinicaltrials.gov/study/NCT04552886 20. Besta FIRCCSINC. A Phase I Study ofImmunotherapy With GSC -Loaded DendriticCells in Patients With RecurrentGlioblastoma 2019 [Available from:https://clinicaltrials.gov/study/NCT02820584 21. Jonsson-Comprehensive-Cancer-Center. Phase IStudy of Glioma-Associated Antigen (GAA)Peptide-pulsed Dendritic Cell Vaccination inMalignant Glioma Patients 2015[05/11/2024]. Available from:https://clinicaltrials.gov/study/NCT0061200122. University-of-Florida. ATTAC-II: A Phase IIRandomized, Blinded, and Placebocontrolled Trial of CMV RNA-Pulsed DendriticCells With Tetanus-Diphtheria Toxoid Vaccinein Patients With NewlyDiagnosedGlioblastoma 2024 [Available from:https://clinicaltrials.gov/study/NCT0246526823. A Phase 1 Trial of CMV RNA-Pulsed Dendritic CellsWith Tetanus-Diphtheria Toxoid Vaccine inPediatric Patients and Young Adults With WHOGrade IV Glioma, Recurrent Malignant Glioma,or Recurrent Medulloblastoma 2021 [Availablefrom: https://clinicaltrials.gov/study/NCT03615404 24. Jonsson-Comprehensive-Cancer-Center. Phase IDose Escalation Study of Autologous Tumorplus radiotherapy-temozolomide for newlydiagnosed glioblastoma. N Engl J Med.2014;370(8):709-22.7. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS,Blumenthal DT, Vogelbaum MA, et al. Arandomized trial of bevacizumab for newlydiagnosed glioblastoma. N Engl J Med.2014;370(8):699-708.8. Narita Y. Bevacizumab for glioblastoma. TherClin Risk Manag. 2015;11:1759-65.9. Celldex-Therapeutics. A Phase II Study of CDX110 With Radiation and Temozolomide inPatients With Newly Diagnosed GlioblastomaMultiforme 2018 [Available from:https://clinicaltrials.gov/study/NCT00458601?cond=Glioblastoma%20Multiforme&intr=CDX-110&rank=1.10. Weller M, Butowski N, Tran DD, Recht LD, LimM, Hirte H, et al. Rindopepimut withtemozolomide for patients with newlydiagnosed, EGFRvIII-expressing glioblastoma(ACT IV): a randomised, double-blind,international phase 3 trial. Lancet Oncol.2017;18(10):1373-85.11. Celldex-Therapeutics. An International,Randomized, Double-Blind, Controlled Studyof Rindopepimut/GM-CSF With AdjuvantTemozolomide in Patients With NewlyDiagnosed, Surgically Resected, EGFRvIIIpositive Glioblastoma 2018 [Available from:https://clinicaltrials.gov/study/NCT01480479.12. Celldex-Therapeutics. A Phase II Study ofRindopepimut/GM-CSF in Patients WithRelapsed EGFRvIII-Positive Glioblastoma2020 [Available from:https://clinicaltrials.gov/study/NCT01498328 13. Schuster J, Lai RK, Recht LD, Reardon DA,Paleologos NA, Groves MD, et al. A phase II,multicenter trial of rindopepimut (CDX-110)in newly diagnosed glioblastoma: the ACT IIIstudy. Neuro Oncol. 2015;17(6):854-61.14. Bunse L, Bunse T, Kramer C, Chih YC, Platten M.Clinical and Translational Advances in GliomaImmunotherapy. Neurotherapeutics.2022;19(6):1799-817.15. Immatics-Biotechnologies-GmbH. A Phase I Trial62ANALESRANFwww.analesranf.comof Actively Personalized Peptide VaccinationsPlus Immunomodulators in Patients WithNewly Diagnosed Glioblastoma Concurrent toFirst Line Temozolomide MaintenanceTherapy 2018 [Available from:Immunotherapy against glioblastoma multiformeLuc%u00eda S%u00e1nchez Prieto y %u00c1ngel Cuesta Mart%u00ednezAn. R. Acad. Farm.vol. 91. n%u00ba1 (2025) %u00b7 pp. 45-66